Yuetiva Deming

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1203011/publications.pdf

Version: 2024-02-01

49 papers	2,327 citations	331259 21 h-index	329751 37 g-index
62 all docs	62 docs citations	62 times ranked	4064 citing authors

#	Article	IF	Citations
1	Exploring common genetic contributors to neuroprotection from amyloid pathology. Brain Communications, 2022, 4, fcac066.	1.5	10
2	Cerebrospinal fluid metabolomics identifies 19 brain-related phenotype associations. Communications Biology, 2021, 4, 63.	2.0	28
3	African Americans Have Differences in CSF Soluble TREM2 and Associated Genetic Variants. Neurology: Genetics, 2021, 7, e571.	0.9	27
4	CSF metabolites associate with CSF tau and improve prediction of Alzheimer's disease status. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2021, 13, e12167.	1.2	2
5	Association of anticholinergic medication and AD biomarkers among cognitively normal late middleâ€age adults: Results from the Wisconsin Registry for Alzheimer's Prevention (WRAP). Alzheimer's and Dementia, 2021, 17, .	0.4	0
6	CSF polygenic risk AD biomarkers predict brain amyloid and free recall. Alzheimer's and Dementia, 2021, 17, .	0.4	1
7	CSF sphingomyelin metabolites in Alzheimerâ€™s disease, neurodegeneration, and neuroinflammation. Alzheimer's and Dementia, 2021, 17, .	0.4	4
8	Diet and APOE as moderators of the relationship between trimethylamine Nâ€oxide and biomarkers of Alzheimer's disease and glial activation. Alzheimer's and Dementia, 2021, 17, e051827.	0.4	2
9	The TMEM106B FTLD-protective variant, rs1990621, is also associated with increased neuronal proportion. Acta Neuropathologica, 2020, 139, 45-61.	3.9	51
10	Higher CSF sTREM2 and microglia activation are associated with slower rates of betaâ€amyloid accumulation. EMBO Molecular Medicine, 2020, 12, e12308.	3.3	73
11	Protective genetic variants in the MS4A gene cluster modulate microglial activity. Alzheimer's and Dementia, 2020, 16, e039431.	0.4	1
12	Identification of blood eQTLs for AD risk loci. Alzheimer's and Dementia, 2020, 16, e043801.	0.4	0
13	Multimodal genomeâ€wide metaâ€analysis of brain amyloidosis reveals heterogeneity across CSF, PET, and pathological amyloid measures. Alzheimer's and Dementia, 2020, 16, e046009.	0.4	0
14	Principal components from untargeted CSF metabolomics associated with tau. Alzheimer's and Dementia, 2020, 16, e046065.	0.4	1
15	Exploring genetic contributors to neuroprotection from AD pathologies: A genomeâ€wide association study. Alzheimer's and Dementia, 2020, 16, e046417.	0.4	0
16	The MS4A gene cluster is a key modulator of soluble TREM2 and Alzheimerâ€™s disease risk. Science Translational Medicine, 2019, 11, .	5.8	170
17	Sex differences in the genetic predictors of Alzheimerâ€™s pathology. Brain, 2019, 142, 2581-2589.	3.7	65
18	Increased soluble TREM2 in cerebrospinal fluid is associated with reduced cognitive and clinical decline in Alzheimerâ€™s disease. Science Translational Medicine, 2019, 11, .	5.8	192

#	Article	IF	Citations
19	Early increase of CSF sTREM2 in Alzheimerâ€™s disease is associated with tau related-neurodegeneration but not with amyloid-Î² pathology. Molecular Neurodegeneration, 2019, 14, 1.	4.4	253
20	Assessment of the Genetic Architecture of Alzheimerâ€™s Disease Risk in Rate of Memory Decline. Journal of Alzheimer's Disease, 2018, 62, 745-756.	1.2	45
21	An APOE -independent cis -eSNP on chromosome 19q13.32 influences tau levels and late-onset Alzheimer's disease risk. Neurobiology of Aging, 2018, 66, 178.e1-178.e8.	1.5	12
22	Polygenic risk score of sporadic lateâ€onset Alzheimer's disease reveals a shared architecture with the familial and earlyâ€onset forms. Alzheimer's and Dementia, 2018, 14, 205-214.	0.4	109
23	P2â€105: NOMINATION OF NOVEL CANDIDATE GENES FOR FAMILIAL LATE ONSET ALZHEIMER DISEASE AFTER EVALUATION OF GENEâ€BASED FAMILYâ€BASED METHODS. Alzheimer's and Dementia, 2018, 14, P709.	0.4	0
24	P1â€139: THE CONTRIBUTION OF SEXâ€SPECIFIC ASSOCIATIONS IN GENETIC STUDIES OF ALZHEIMER'S DISEASE PATHOLOGY. Alzheimer's and Dementia, 2018, 14, P327.	0.4	0
25	S1-02-01: REVIEW OF GWAS GENES AND POLYGENIC RISK SCORES. , 2018, 14, P198-P198.		0
26	<scp>CSF</scp> progranulin increases in the course of Alzheimer's disease and is associated with <scp>sTREM</scp> 2, neurodegeneration and cognitive decline. EMBO Molecular Medicine, 2018, 10, .	3.3	64
27	Genome-wide association study for variants that modulate relationships between cerebrospinal fluid amyloid-beta 42, tau, and p-tau levels. Alzheimer's Research and Therapy, 2018, 10, 86.	3.0	18
28	Sex-specific genetic predictors of Alzheimerâ€™s disease biomarkers. Acta Neuropathologica, 2018, 136, 857-872.	3.9	87
29	Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease. Frontiers in Neuroscience, 2018, 12, 209.	1.4	21
30	Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?. Expert Opinion on Therapeutic Targets, 2018, 22, 587-598.	1.5	27
31	Genome-wide association study identifies four novel loci associated with Alzheimerâ€™s endophenotypes and disease modifiers. Acta Neuropathologica, 2017, 133, 839-856.	3.9	199
32	CSF protein changes associated with hippocampal sclerosis risk gene variants highlight impact of GRN/PGRN. Experimental Gerontology, 2017, 90, 83-89.	1.2	7
33	A common haplotype lowers PU.1 expression in myeloid cells and delays onset of Alzheimer's disease. Nature Neuroscience, 2017, 20, 1052-1061.	7.1	330
34	[O1â€“11â€“03]: CEREBROSPINAL FLUID ENDOPHENOTYPES PROVIDE INSIGHT INTO BIOLOGY UNDERLYING ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P218.	0.4	0
35	Analysis of neurodegenerative Mendelian genes in clinically diagnosed Alzheimer Disease. PLoS Genetics, 2017, 13, e1007045.	1.5	40
36	Identification of plexin A4 as a novel clusterin receptor links two Alzheimerâ€™s disease risk genes. Human Molecular Genetics, 2016, 25, 3467-3475.	1.4	21

#	Article	IF	Citations
37	Genetic studies of plasma analytes identify novel potential biomarkers for several complex traits. Scientific Reports, 2016, 6, .	1.6	25
38	Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurology, 2016, 16, 217.	0.8	12
39	P3â€097: SORL1 Variants Across Alzheimerâ€™s Disease Cohorts in European Americans. Alzheimer's and Dementia, 2016, 12, P857.	0.4	0
40	O2â€10â€06: A Common Allele in SPI1 Lowers Risk and Delays Age at Onset for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P253.	0.4	0
41	SORL1 variants across Alzheimerâ€™s disease European American cohorts. European Journal of Human Genetics, 2016, 24, 1828-1830.	1.4	20
42	O2â€10â€05: Cerebrospinal Fluid Levels of Amyloid Beta and Tau as Endophenotypes Reveal Novel Variants Potentially Informative for Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P252.	0.4	0
43	A potential endophenotype for Alzheimer's disease: cerebrospinal fluid clusterin. Neurobiology of Aging, 2016, 37, 208.e1-208.e9.	1.5	44
44	Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathologica, 2016, 131, 925-933.	3.9	262
45	Pooled-DNA Sequencing for Elucidating New Genomic Risk Factors, Rare Variants Underlying Alzheimerâ€™s Disease. Methods in Molecular Biology, 2016, 1303, 299-314.	0.4	3
46	O4-05-06: A potential endophenotype for Alzheimer's disease: Cerebrospinal fluid clusterin. , 2015, 11, P280-P280.		0
47	Role of ABCA7 loss-of-function variant in Alzheimer's disease: a replication study in Europeanâ€“Americans. Alzheimer's Research and Therapy, 2015, 7, 73.	3.0	24
48	Reversal of Established Traumatic Brain Injury-Induced, Anxiety-Like Behavior in Rats after Delayed, Post-Injury Neuroimmune Suppression. Journal of Neurotrauma, 2014, 31, 487-497.	1.7	25
49	TMEM106B: a strong FTLD disease modifier. Acta Neuropathologica, 2014, 127, 419-422.	3.9	24